Get started
Author

Marina N. Nechaeva

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
2023 · Shukui Qin, Stephen L Chan, et al. · The Lancet · 827
Atezolizumab and nab -Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
2021 · Leisha A Emens, Luciana Molinero, et al. · JNCI Journal of the National Cancer Institute · 316
PDF
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
2019 · Charles S Fuchs, Kohei Shitara, et al. · The Lancet Oncology · 300
Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer
2019 · LA Emens, S Loi, et al. · Cancer Research · 82
FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma.
2016 · Salah-Eddin Al-Batran, Martin H. Schuler, et al. · Journal of Clinical Oncology · 47
296P Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 trial
2020 · L.A. Emens, L. Molinero, et al. · Annals of Oncology · 30
PDF
Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)
2021 · Dmytro Trukhin, Elena Poddubskaya, et al. · BioDrugs · 27
PDF
Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma
2016 · M. Schuler, S.-E. Al-Batran, et al. · Annals of Oncology · 23
PDF
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial
2025 · P. Schmid, H.L. McArthur, et al. · Annals of Oncology · 19
PDF
LBA51 EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)
2021 · M. Gogishvili, T. Melkadze, et al. · Annals of Oncology · 19
PDF
FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma.
2016 · Salah-Eddin Al-Batran, Martin H. Schuler, et al. · Journal of Clinical Oncology · 16
A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290).
2020 · Peter Schmid, Javier Cortes, et al. · Journal of Clinical Oncology · 15
LBA19 Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial
2024 · P. Schmid, H.L. McArthur, et al. · Annals of Oncology · 11
PDF
Final Results of Phase II Trial (MIRACULUM) of the Novel PD-1 Inhibitor Prolgolimab in Patients with Advanced Melanoma
2019 · S. Tjulandin, M. Fedyanin, et al. · Annals of Oncology · 9
Abstract OT2-08-02: Capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer: A phase III trial (CAPItello-290)
2020 · Peter Schmid, Javier Cortes, et al. · Cancer Research · 8
Final results of a phase II trial of prolgolimab with platinum-based therapy and bevacizumab in patients with advanced cervical cancer.
2023 · Sergey Fogt, Timur Andabekov, et al. · Journal of Clinical Oncology · 5
O009/#786 Rucaparib vs chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious brca mutation: efficacy and safety from ariel4, a randomized phase 3 study
2021 · R. Kristeleit, A. Lisyanskaya, et al. · International Journal of Gynecological Cancer · 4
220O Claudin 18.2 - a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer
2016 · F. Lordick, M. Schuler, et al. · Annals of Oncology · 3
PDF
1261TiP CARMEN-GC01: Phase II, open-label, single-arm study of tusamitamab ravtansine in combination with ramucirumab in pretreated patients with gastric or gastroesophageal junction adenocarcinoma (GA/GEJA)
2022 · F.M. Esposito, J. Lee, et al. · Annals of Oncology · 2
Complex Relationships Between Homologous Recombination Deficiency (HRD) Score and Mutational Status of Homologous Recombination Repair (HRR) Genes in Prostate Carcinomas
2025 · Aglaya G. Iyevleva, Svetlana N. Aleksakhina, et al. · International Journal of Molecular Sciences · 1
PDF
93P Patient-reported outcomes (PROs) with cemiplimab or placebo plus platinum-doublet chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 3 trial
2021 · T. Makharadze, R.G. Quek, et al. · Annals of Oncology · 1
PDF
1495P Cemiplimab plus chemotherapy versus chemotherapy in non-small cell lung cancer with PD-L1 ≥1%: EMPOWER-Lung 3 results
2023 · A. Baramidze, T. Makharadze, et al. · Annals of Oncology
PDF
IMpassion130: Efficacy in immune biomarker subgroups of atezolizumab plus nab-paclitaxel in patients with triple-negative BC
2019 · Roger von Moos, Leisha A. Emens, et al. · Swiss Medical Weekly
2223 Pattern of treatment and survival in localized gastric cancer in 2000–2013: A population-based analysis from North-Western Russia
2015 · M. Valkov, M. Nechaeva, et al. · European Journal of Cancer
1004 Survival of lung cancer patients residing in the Russian Atomic Shipbuilding Center, Northwest Russia
2015 · E. Solovyova, M. Nechaeva, et al. · European Journal of Cancer
Works count: 25
Citation count: 1,765
H-index: 12
I10-index: 13
Year
Topic
Type